FUTURESYNTHESIS SP ZOO

Their core work

FutureSynthesis is a Polish biotech SME working at the frontier of nucleic acid nanotechnology — the design and engineering of RNA and DNA as programmable molecular tools. Their work spans molecular machines for DNA repair to AI-assisted RNA delivery systems capable of transferring genetic information into living cells. They contribute specialized research expertise to international European consortia, with a particular focus on RNA origami architectures and mRNA-based cellular delivery mechanisms. Based in Poznan, they operate at the intersection of molecular biology, synthetic biology, and computational molecular design.

What they specialise in

How they've shifted over time

FutureSynthesis entered H2020 through the DNAREPAIRMAN training network (2017-2020), contributing to DNA-focused molecular machine research — a field grounded in structural biology and repair pathway analysis. Their second project, DESTINATION (2021-2025), marks a clear pivot toward RNA nanotechnology and mRNA origami-based delivery, reflecting the broader biotech shift triggered by advances in mRNA therapeutics. The trajectory — from DNA repair machines to programmable RNA delivery systems with AI integration — suggests deliberate repositioning into one of biotechnology's most commercially active areas.

FutureSynthesis is moving deeper into AI-assisted RNA delivery and mRNA engineering, positioning them as a natural fit for consortia working on gene therapy, mRNA vaccines, or programmable cellular systems.

How they like to work

FutureSynthesis has participated exclusively as a consortium partner — never as a coordinator — across both projects, indicating they function as specialist contributors rather than project organizers. Despite only two projects, they have engaged with 18 unique partners across 7 countries, suggesting active participation in sizable, multi-institutional European consortia typical of MSCA and FET programs. This profile points to an organization that is sought out for specific technical depth, not for administrative or project management capacity.

FutureSynthesis has built a network of 18 unique partners across 7 countries from just two projects, indicating broad engagement within large European research consortia rather than deep bilateral ties. Their geographic reach is distributed across Europe, consistent with the international makeup of MSCA and FET program partnerships.

What sets them apart

FutureSynthesis is a rare Polish private SME operating at the research frontier of RNA nanotechnology and synthetic biology — a space almost entirely occupied by academic institutions and large pharmaceutical companies. Their dual participation in an MSCA training network and a FET frontier research project demonstrates credibility across both capacity-building and high-risk/high-reward research contexts. For consortium builders seeking an SME partner with genuine RNA/DNA nanotechnology expertise anchored in Central Europe, FutureSynthesis fills a niche few Polish private companies can credibly claim.

Highlights from their portfolio

• DESTINATION
  Directly targets AI-enabled mRNA delivery into cells — one of the most commercially significant research directions in post-2020 biotech, making this their highest-potential project for future technology transfer.
• DNAREPAIRMAN
  An MSCA Innovative Training Network, signaling that FutureSynthesis has served as a research host for early-career scientists, which adds an education and training dimension to their consortium value.